RespireRx Pharmaceuticals Inc

RespireRx Pharmaceuticals — Investor Presentation (September 2022)

23 slides from RespireRx Pharmaceuticals's investor presentation, Sep 13, 2022

  1. Slide 1: Drug Re-purposing: A Case Study of Dronabinol

    RespireRx Pharmaceuticals Inc OTC QB: RSPI Drug Re-purposing: A Case Study of Dronabinol September 7, 2022

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements RespireRx Pharmaceuticals Inc -EORWARD LOOKING STATEMENTS ‘This presentation contains certain forward-looking statements within the meaning of Section 278 ofthe Secures Act of 1933, as amended (the “Securities Act’) and Section 216 of the Secures Exchange Act of 1934, as a

  3. Slide 3: RespireRx - Product Development Status

    RespireRx - Product Development Status GdResp pireRx Pharmaceuticals Inc Preclinical Phase 1 Phase 2 Phase 3 ResolutionRx - Cannabinoids Dronabinol — OSA —_———— EndeavourRx - Neuromodulators AMPAkines CX717 - ADHD TS €X1739- Spinal Cord 1}. ll €X1942 -follow-up compound > GABAkines KRM-II-81 — Epile

  4. Slide 4: Attractiveness of Re-Purposing of Dronabinol

    Attractiveness of Re-Purposing of Dronabinol RespireRx 1. Development of Pharmaceutical Cannabinoids - refers to the development of cannabinoids according to FDA and other foreign accepted regulatory pathways by which a company receives approval to market and sell a new drug. 2. Defined Regulatory R

  5. Slide 5: Dronabinol Reduces Apnea in OSA Patients

    nabinol Reduces Apnea in OSA Patients RespireRx Pharmaceuticals Inc Phase 2A Proof of Concept Trial of Dronabinol in OSA [40% x ZL, 30% xe co 3-Week Dose-ascending Study oy 2K = 32 n=17 ES 10% - = : WE Dronabinol* © Statistical Analysis Across All ao O% Doses & Times ce 2, 10% Placebo oo ae: Ds -20%

  6. Slide 6: Obstructive Sleep Apnea is a National Epidemic

    Obstructive Sleep Apnea is a National Epidemic (R)Resp pireRx Pharmaceuticals Inc Estimated Annual Estimated Annual Indicated Drug Disease State US Prevalence Cost to Society Therapy Expenditures OSAtS 29.4 MM $162.0 Billion $0 Asthma®’ 16.4 MM $18.3 Billion $13.5 Billion Hypertension®19 43.2 MM $73

  7. Slide 7: Difficulties Unique to Dronabinol

    Difficulties Unique to Dronabinol RespireRx Pharmaceuticals Inc 1. Banks - Confused pharmaceutical cannabinoids with plant cannabis growing and sales 2. Fund Raising — Cannabis investors focused on sales of plant based cannabis and traditional investors confused pharmaceutical cannabinoids with cann

  8. Slide 8: The PACE Clinical Trial: Phase 2B Study

    THE PACE Clinical Trial: Pharmacotherapy of Apnea by Cannabimimetic Enhancement — A Phase 2B Study RespireRx Pharmaceuticals Inc Randomized, Placebo-controlled, Parallel Groups, Multi-site Trial in Patients with Moderate to Severe OSA, n=73 Study Drug: Dronabinol (Overencapsulated Marinol®): 2.5 mg

  9. Slide 9: The Phase 2B PACE Trial in OSA: Final Overall Results

    The Phase 2B PACE Trial in OSA: Final Overall RespireRx Statistically significant improvement in Primary Outcome Measures ¢ Apnea-Hypopnea Index (AHI) (2.5 and 10 mg) ¢ ESS Sleepiness Scale (10 mg) * Overall Patient Satisfaction (10 mg)

  10. Slide 10: Results of 6-Week Treatment: Dronabinol Reduces AHI

    sults of 6-Week Treatme! Dronabinol Reduces AHI RespireRx Pharmaceuticals Inc Positive Effects of Dronabinol vs. Placebo in TOTAL, REM & NREM Sleep Demonstrate Efficacy Change in Apnea/Hypopnea Index 10 10 mTST mNREM mREM . l l ee * & Placebo 2.5 mgiday 40 mg/day Dronabinol Dose Compared to placebo

  11. Slide 11: The PACE Trial Replicates the Phase 2A Study

    The Pace Trial Replicates the Phase 2A Study! RespireRx Pharmaceuticals Inc *** 9.02, compared to placebo for Phase 2A Two Phase 2 Trials Have 35 Shown that Dronabinol a0 Treatment Results ina Statistically Significant, Dose Related Improvement Apnea-Hypopnia Index (AHI) 15 10 Phase 2K in AHI, the P

  12. Slide 12: Dronabinol Reduces Daytime Sleepiness

    abinol Reduces Daytime Sleepiness RespireRx Pharmaceuticals Inc Change in Epworth Sleepiness Scale 7 Placebo 2.5mgiday 10mgiday Dronabinol Dose * p<0.05, compared to placebo ACE sca [Benne Clinical Trial 12

  13. Slide 13: Dronabinol Improves MWT

    Dronabinol Improves MWT RespireRx Pharmaceuticals Inc Change in Mean Wakefulness Testing (MWT) A 12 _ 10 = 8 3 6 24 a ¢ 2 go 2 2 gz 4 <i .¢ * 8 oe ——— “40 pA harmacatherapy of Placebo 2.5mg/day 10 mg/day Dronabinol Dose 13

  14. Slide 14: Dronabinol Has an Excellent Safety Profile

    onabinol Has an Excellent Safety Profile RespireRx Pharmaceuticals Inc Great Majority of AEs were mild to moderate + Average Number of AEs = 4.1+4.0 + AEs did not differ by treatment group + Most Frequent Verbatim AEs Reported Were: - Sleepiness/Drowsiness (N=25) - Headache (N=24) - Nausea/Vomiting

  15. Slide 15: New Formulations Based on Clinical Data

    New Formulations Based on Clinical Data RespireRx Pharmaceuticals Inc Change in AHI in the 1%‘ 4 hours vs. the 2"4 4 hours of the night + Low dose dronabinol is as effective as the high dose in the first half of the night + Effectiveness mist Half diminishes in the second half of the night 2nd Half

  16. Slide 16: Present Dronabinol Gel-cap Formulations

    Present Dronabinol Gel-cap Formulations RespireRx Pharmaceuticals Inc ¢ Poor and erratic absorption, with some patients achieving very high levels and others achieving very low levels. © Dronabinel oral solution 4.25 mg (replicate 1) -& Dronabinol oral solution 4.25 mg (replicate 2) “Ax Dronabinol c

  17. Slide 17: Present Dronabinol Gel-cap Formulations

    Present Dronabinol Gel-cap Formulations BW RespireRx Pharmaceuticals Inc ¢ Poor and erratic absorption, with some patients achieving very high levels and others achieving very low levels. * Rapid and extensive first-pass liver metabolism, resulting in low blood levels and a relatively short half-lif

  18. Slide 18: Lipid-based Cannabinoid Formulations

    Lipid-based Cannabinoid Formulations GQ Resp pireRx Intended Goals 1. Soluble with appropriate dissolution 2. Particle size in the 50 - 150 nM range 3. Room temperature stability 4. Resistant to disturbance by stomach acids 5. Lymphatic absorption to bypass liver metabolism 6. Encapsulation efficien

  19. Slide 19: Lipid-based Cannabinoid Formulations

    id-based Canna Formulations RespireRx Pharmaceuticals Inc Clear, no visible phase separation 19

  20. Slide 20: Lipid-based Cannabinoid Formulations

    Lipid-based Cannabinoid Formulations >) RespireRx Pharmaceuticals Inc 250 =m g 10 bor a wo 2 a rf = " =z * ° ZIQTVAVIVI SSS Lipid-based Formulations Lia-based Formulations i» Formulations <. <=. Bi Dronabinol/ethanol en » 3 so * = = ca) E ia = HEEL rm % 10 ° . “ . . Lipid-based Formulations sme 20

  21. Slide 21: Remaining Issues

    Remaining Issues RespireRx Pharmaceuticals Inc 1. Pharmacokinetics 2. Clinical Dosage Forms — partner with larger firm to create supply of clinical material. 2. Pre-IND Meeting with FDA 3. FUNDING!!!! 21

  22. Slide 22: RespireRx: ResolutionRx and EndeavourRx

    WN RespireRx respiren Inc ResolutionRx* EndeavourRx* Pharmaceutical Cannabinoids Neuromodulators * See respective business plans

  23. Slide 23: Business Ur

    rm Business Ur Pharmaceuticals Inc

RespireRx Pharmaceuticals — Investor Presentation (September 2022) on 6ix